Literature DB >> 18725458

Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response.

Benjamin Keserü1, Eduardo Barbosa-Sicard, Rüdiger Popp, Beate Fisslthaler, Alexander Dietrich, Thomas Gudermann, Bruce D Hammock, John R Falck, Norbert Weissmann, Rudi Busse, Ingrid Fleming.   

Abstract

Recent findings have indicated a role for cytochrome P-450 (CYP) epoxygenase-derived epoxyeicosatrienoic acids (EETs) in acute hypoxic pulmonary vasoconstriction (HPV). Given that the intracellular concentration of EETs is determined by the soluble epoxide hydrolase (sEH), we assessed the influence of the sEH and 11,12-EET on pulmonary artery pressure and HPV in the isolated mouse lung. In lungs from wild-type mice, HPV was significantly increased by sEH inhibition, an effect abolished by pretreatment with CYP epoxygenase inhibitors and the EET antagonist 14,15-EEZE. HPV and EET production were greater in lungs from sEH(-/-) mice than from wild-type mice and sEH inhibition had no further effect on HPV, while MSPPOH and 14,15-EEZE decreased the response. 11,12-EET increased pulmonary artery pressure in a concentration-dependent manner and enhanced HPV via a Rho-dependent mechanism. Both 11,12-EET and hypoxia elicited the membrane translocation of a transient receptor potential (TRP) C6-V5 fusion protein, the latter effect was sensitive to 14,15-EEZE. Moreover, while acute hypoxia and 11,12-EET increased pulmonary pressure in lungs from TRPC6(+/-) mice, lungs from TRPC6(-/-) mice did not respond to either stimuli. These data demonstrate that CYP-derived EETs are involved in HPV and that EET-induced pulmonary contraction under normoxic and hypoxic conditions involves a TRPC6-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18725458      PMCID: PMC2614611          DOI: 10.1096/fj.08-112821

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  45 in total

1.  20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase.

Authors:  Voahanginirina Randriamboavonjy; Rudi Busse; Ingrid Fleming
Journal:  Hypertension       Date:  2002-12-16       Impact factor: 10.190

2.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

3.  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases.

Authors:  Christophe Morisseau; Marvin H Goodrow; John W Newman; Craig E Wheelock; Deanna L Dowdy; Bruce D Hammock
Journal:  Biochem Pharmacol       Date:  2002-05-01       Impact factor: 5.858

4.  Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries.

Authors:  D Zhu; M Bousamra; D C Zeldin; J R Falck; M Townsley; D R Harder; R J Roman; E R Jacobs
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-02       Impact factor: 5.464

5.  14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries.

Authors:  Kathryn M Gauthier; Christina Deeter; U Murali Krishna; Y Krishna Reddy; Muralidhar Bondlela; J R Falck; William B Campbell
Journal:  Circ Res       Date:  2002-05-17       Impact factor: 17.367

6.  Hypoxic pulmonary vasoconstriction is modified by P-450 metabolites.

Authors:  D Zhu; E K Birks; C A Dawson; M Patel; J R Falck; K Presberg; R J Roman; E R Jacobs
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-10       Impact factor: 4.733

7.  Cytosolic phospholipase A(2) in hypoxic pulmonary vasoconstriction.

Authors:  Fumito Ichinose; Roman Ullrich; Adam Sapirstein; Rosemary C Jones; Joseph V Bonventre; Charles N Serhan; Kenneth D Bloch; Warren M Zapol
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 8.  P-450 metabolites of arachidonic acid in the control of cardiovascular function.

Authors:  Richard J Roman
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

9.  Differential effects of 5,6-EET on segmental pulmonary vasoactivity in the rabbit.

Authors:  Alan H Stephenson; Randy S Sprague; Jennifer L Losapio; Andrew J Lonigro
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-02-27       Impact factor: 4.733

10.  Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.

Authors:  Oliver Jung; Ralf P Brandes; In-Hae Kim; Frank Schweda; Ronald Schmidt; Bruce D Hammock; Rudi Busse; Ingrid Fleming
Journal:  Hypertension       Date:  2005-02-07       Impact factor: 10.190

View more
  50 in total

1.  Soluble epoxide hydrolase: sex differences and role in endothelial cell survival.

Authors:  Nandita C Gupta; Catherine M Davis; Jonathan W Nelson; Jennifer M Young; Nabil J Alkayed
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

2.  The biological actions of 11,12-epoxyeicosatrienoic acid in endothelial cells are specific to the R/S-enantiomer and require the G(s) protein.

Authors:  Yindi Ding; Timo Frömel; Rüdiger Popp; John R Falck; Wolf-Hagen Schunck; Ingrid Fleming
Journal:  J Pharmacol Exp Ther       Date:  2014-04-24       Impact factor: 4.030

Review 3.  Transient receptor potential channels in the vasculature.

Authors:  Scott Earley; Joseph E Brayden
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

4.  High potassium intake enhances the inhibitory effect of 11,12-EET on ENaC.

Authors:  Peng Sun; Dao-Hong Lin; Peng Yue; Houli Jiang; Katherine H Gotlinger; Michal L Schwartzman; John R Falck; Mohan Goli; Wen-Hui Wang
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

5.  CFTR and sphingolipids mediate hypoxic pulmonary vasoconstriction.

Authors:  Christoph Tabeling; Hanpo Yu; Liming Wang; Hannes Ranke; Neil M Goldenberg; Diana Zabini; Elena Noe; Adrienn Krauszman; Birgitt Gutbier; Jun Yin; Michael Schaefer; Christoph Arenz; Andreas C Hocke; Norbert Suttorp; Richard L Proia; Martin Witzenrath; Wolfgang M Kuebler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-17       Impact factor: 11.205

6.  Hypoxic pulmonary vasoconstriction requires connexin 40-mediated endothelial signal conduction.

Authors:  Liming Wang; Jun Yin; Hannah T Nickles; Hannes Ranke; Arata Tabuchi; Julia Hoffmann; Christoph Tabeling; Eduardo Barbosa-Sicard; Marc Chanson; Brenda R Kwak; Hee-Sup Shin; Songwei Wu; Brant E Isakson; Martin Witzenrath; Cor de Wit; Ingrid Fleming; Hermann Kuppe; Wolfgang M Kuebler
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

Review 7.  Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem.

Authors:  Jeremy P T Ward; Ivan F McMurtry
Journal:  Curr Opin Pharmacol       Date:  2009-03-16       Impact factor: 5.547

8.  Cimetidine-associated patent ductus arteriosus is mediated via a cytochrome P450 mechanism independent of H2 receptor antagonism.

Authors:  Robert B Cotton; Lisa P Shah; Stanley D Poole; Noah J Ehinger; Naoko Brown; Elaine L Shelton; James C Slaughter; H Scott Baldwin; Bibhash C Paria; Jeff Reese
Journal:  J Mol Cell Cardiol       Date:  2013-02-27       Impact factor: 5.000

9.  Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease.

Authors:  Oliver Jung; Felix Jansen; Anja Mieth; Eduardo Barbosa-Sicard; Rainer U Pliquett; Andrea Babelova; Christophe Morisseau; Sung H Hwang; Cindy Tsai; Bruce D Hammock; Liliana Schaefer; Gerd Geisslinger; Kerstin Amann; Ralf P Brandes
Journal:  PLoS One       Date:  2010-08-04       Impact factor: 3.240

Review 10.  ROS-dependent signaling mechanisms for hypoxic Ca(2+) responses in pulmonary artery myocytes.

Authors:  Yong-Xiao Wang; Yun-Min Zheng
Journal:  Antioxid Redox Signal       Date:  2010-03-01       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.